Oral and Topical Treatment of Experimental Herpes Simplex Iritis With Bromovinyldeoxyuridine

• Oral treatment of rabbits with bromovinyldeoxyuridine ([<i>E</i>]-5-[2-bromovinyl]2′-deoxyuridine) at 10 or 100 mg/kg/day for four days significantly reduced the severity of herpes simplex iritis. This effect was not potentiated by the concomitant subconjunctival injection of sustained-action betamethasone. A significant reduction in the severity of herpetic iritis was also observed on topical application of bromovinyldeoxyuridine, and, in this regard, 0.5% bromovinyldeoxyuridine eyedrops proved significantly more efficacious than 1% trifluridine eyedrops.